A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDSUlrich Keilholz, Carmen Scheibenbogen, Wolf-Karsten Hofmann et al.|Blood|2009Cited by 300
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemiaCarmen Scheibenbogen, Ulrich Keilholz, Anne Letsch et al.|Blood|2002Cited by 251
Natural T cell immunity against cancer.Dirk Nagorsen, Ulrich Keilholz, Anne Letsch et al.|PubMed|2003Cited by 196